The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies

被引：0
|
作者：
Weber, Martin [1 ,2 ,3 ]
Kappos, Ludwig [4 ]
Hauser, Stephen [5 ]
Nicholas, Jacqueline [6 ]
Schneble, Hans-Martin [7 ]
Wang, Qing [7 ]
Giovannoni, Gavin [8 ]
Filippi, Massimo [9 ,10 ]
机构：
[1] Inst Neuropathol, Dept Neurol, Gottingen, Germany
[2] Univ Med Ctr, Gottingen, Germany
[3] Fraunhofer Inst Translat Med & Pharmacol ITMP, Gottingen, Germany
[4] Univ Basel, Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci, Basel, Switzerland
[5] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA USA
[6] OhioHlth Multiple Sclerosis Clin, Columbus, OH USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Queen Mary Univ London, London, England
[9] IRCCS San Raffaele Sci Inst, Neurol Unit, Neurophysiol Serv, Neurorehabil Unit,Neuroimaging Res Unit,Div Neuro, Milan, Italy
[10] Univ Vita Salute San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P302/406
引用
收藏
页码：350 / 351
页数：2
相关论文
共 50 条
  • [41] Sexual dimorphism in the long-term stability (10 years) of skeletal Class III treatment
    Natalia Tejedor
    Conchita Martín
    José Antonio Alarcón
    María Dolores Oteo-Calatayud
    Juan Carlos Palma-Fernández
    Progress in Orthodontics, 22
  • [42] Sexual dimorphism in the long-term stability (10 years) of skeletal Class III treatment
    Tejedor, Natalia
    Martin, Conchita
    Antonio Alarcon, Jose
    Dolores Oteo-Calatayud, Maria
    Carlos Palma-Fernandez, Juan
    PROGRESS IN ORTHODONTICS, 2021, 22 (01)
  • [43] Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis
    Hauser, S.
    Comi, G.
    Hartung, H. -P.
    Selmaj, K.
    Traboulsee, A.
    Bar-Or, A.
    Arnold, D.
    Klingelschmitt, G.
    Leppert, D.
    Kakarieka, A.
    Lublin, F.
    Garren, H.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 752 - 752
  • [44] CARIMS (Cancer Risk in Multiple Sclerosis) project: impact of long-term treatment.
    Lebrun, C.
    Debouverie, M.
    Vermersch, P.
    Clavelou, P.
    Rumbach, L.
    de Seze, J.
    Defer, G.
    Berthier, F.
    REVUE NEUROLOGIQUE, 2007, 163 (01) : 38 - 46
  • [45] Impact of Diagnosis and Treatment Timing on Long-Term Outcomes in Multiple Sclerosis: A Comprehensive Study
    Ozakbas, Serkan
    Samadzade, Ulvi
    Kara, Irem
    Unal, Gozde Deniz
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1178 - 1178
  • [46] Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies
    Papeix, C.
    Cree, B.
    Turner, B.
    Kappos, L.
    Montalban, X.
    Wolinsky, J. S.
    Buffels, R.
    Garren, H.
    Guittari, C. J.
    Han, J.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 332 - 333
  • [47] Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies
    Turner, B.
    Papeix, C.
    Cree, B.
    Kappos, L.
    Montalban, X.
    Wolinsky, J. S.
    Buffels, R.
    Garren, H.
    Guittari, C. J.
    Han, J.
    Hauser, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 333 - 334
  • [48] Confirmed Disability Progression in Different Subgroups of Patients With Relapsing Multiple Sclerosis Who Received Ocrelizumab or Interferon Beta-1a in the Phase III OPERA I and OPERA II Studies
    Turner, Benjamin
    Cree, Bruce
    Lorscheider, Johannes
    Montalban, Xavier
    Papeix, Caroline
    Buffels, Regine
    Masterman, Donna
    Han, Jian
    Levesque, Victoria
    Wolinsky, Jerry
    NEUROLOGY, 2018, 90
  • [49] Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease
    Costelloe, L.
    Thompson, A.
    Walsh, C.
    Tubridy, N.
    Hutchinson, M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (11): : 1245 - 1248
  • [50] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
    Wolinsky, Jerry S.
    Arnold, Douglas L.
    Brochet, Bruno
    Hartung, Hans-Peter
    Montalban, Xavier
    Naismith, Robert T.
    Manfrini, Marianna
    Overell, James
    Koendgen, Harold
    Sauter, Annette
    Bennett, Iain
    Hubeaux, Stanislas
    Kappos, Ludwig
    Hauser, Stephen L.
    LANCET NEUROLOGY, 2020, 19 (12): : 998 - 1009
12345